Aigen Investment Management LP Has $1.84 Million Holdings in Danaher Co. (NYSE:DHR)

Aigen Investment Management LP trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 25.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,005 shares of the conglomerate’s stock after selling 2,750 shares during the quarter. Aigen Investment Management LP’s holdings in Danaher were worth $1,838,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in DHR. FMR LLC boosted its holdings in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. Van ECK Associates Corp raised its stake in Danaher by 6,862.7% during the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock worth $213,452,000 after buying an additional 916,513 shares during the last quarter. Proficio Capital Partners LLC boosted its position in shares of Danaher by 29,287.7% during the 4th quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock valued at $135,189,000 after purchasing an additional 586,925 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares during the period. Finally, Fisher Funds Management LTD bought a new stake in Danaher in the fourth quarter valued at $120,718,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

DHR opened at $205.92 on Wednesday. The firm has a 50 day moving average of $223.61 and a two-hundred day moving average of $243.86. The firm has a market capitalization of $147.17 billion, a PE ratio of 39.00, a P/E/G ratio of 2.66 and a beta of 0.82. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the firm earned $2.09 earnings per share. On average, analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

DHR has been the topic of a number of analyst reports. Citigroup lowered their target price on shares of Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. JPMorgan Chase & Co. lowered their price objective on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Robert W. Baird decreased their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Finally, Guggenheim initiated coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.